Plasma concentration is the amount of a substance dissolved in the liquid portion of your blood at a given moment. It matters because, for drugs, it determines whether a medication is actually working, doing nothing, or causing harm. For natural substances like proteins, electrolytes, and inflammatory markers, plasma concentration gives clinicians a window into what is happening inside your body. The concept sounds simple, but the factors that push a plasma concentration up or down are surprisingly varied, and understanding them changes how drugs are prescribed, how diseases are diagnosed, and how individual patients are kept safe.
What a Plasma Concentration Actually Measures
Blood is not a uniform liquid. It contains red blood cells, white blood cells, platelets, and the fluid they float in. That fluid, once the clotting factors are removed (or left in, depending on how the sample is processed), is what clinicians call plasma or serum. When a lab reports a plasma concentration, it is telling you how much of a specific substance exists per unit volume of that fluid portion alone. This matters because many drugs and biomarkers stay in the fluid rather than entering cells. For some compounds, the difference is dramatic: certain industrial chemicals, for example, show roughly twice the concentration in plasma compared to whole blood, because they do not cross into red blood cells at all, and the measurement difference tracks almost perfectly with the volume that red blood cells displace.1PubMed. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals
The body also tightly controls certain plasma concentrations on its own. Serum osmolality, for instance, is held between about 285 and 290 milliosmoles per kilogram, with sodium as the main driver.2Anaesthesia & Intensive Care Medicine. Physiology Regulation of fluid and electrolyte balance When that number drifts outside range, water shifts between the inside and outside of cells in ways that cause real trouble. This tight regulation is one reason clinicians use plasma concentrations as a diagnostic tool: a value outside the expected window often signals that something has gone wrong.
How the Route a Drug Takes Changes Its Plasma Concentration
If you swallow a pill, the drug has to survive the stomach, cross the intestinal wall, and pass through the liver before it even reaches the general circulation. Each step strips away some of the dose. A drug injected directly into a vein skips all of that and arrives at full strength. The gap between these two scenarios can be enormous. In rat studies of fluoxetine, the oral bioavailability at a low dose was only about 38%, because the liver extracted roughly 60% of the drug on its first pass.3PubMed. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat At higher doses, that first-pass metabolism appeared to become temporarily overwhelmed, and oral bioavailability jumped above what would have been expected, a reminder that dose and route interact in nonlinear ways.
The same drug given by different routes can also produce strikingly different peak concentrations. A study comparing four routes for the drug misoprostol found that placing it under the tongue produced a peak plasma level roughly twice as high as swallowing it and nearly five times higher than vaginal administration.4Human Reproduction. Pharmacokinetics of different routes of administration of misoprostol The sublingual route also delivered a larger total drug exposure over six hours. These are not trivial differences. A prescriber choosing between routes is effectively choosing between very different plasma concentration profiles, each with its own trade-off between how fast the drug kicks in, how high the peak climbs, and how long the effect lasts.
Why Only the Unbound Drug Matters for Effect
Once a drug reaches the bloodstream, a portion of it latches onto proteins, primarily albumin and alpha-1 acid glycoprotein, and rides along like cargo. While attached, the drug cannot cross cell membranes, cannot bind to its target receptor, and cannot produce any therapeutic or toxic effect. Only the unbound, or “free,” fraction does the actual work.5PubMed Central. Re-discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions The relationship is straightforward in theory: after steady state is reached, the free drug concentration in plasma equals the free drug concentration at the target receptor in tissue.6PubMed. Plasma protein binding: from discovery to development Any sudden spike in the free fraction, whether from a competing drug elbowing albumin or from liver disease reducing albumin production, can tip a patient from therapeutic levels into toxic territory without the total plasma concentration changing at all.
This is why clinical trials typically report total drug concentration, but increasingly, researchers and clinicians pay close attention to the unbound fraction as the better predictor of what the drug is actually doing.7PubMed Central. Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States For highly protein-bound drugs, two patients can have the same total plasma concentration yet very different therapeutic responses, simply because their free fractions differ. Advanced lab techniques using ultrafiltration paired with liquid chromatography and mass spectrometry now allow researchers to separately measure total and unbound concentrations for drugs like the chemotherapy agent docetaxel.8Scientific Reports. Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC-MS/MS: application to pharmacokinetic studies
Therapeutic Drug Monitoring
For most medications, doctors prescribe a standard dose and adjust based on how you feel. But for a subset of drugs, “how you feel” is not a reliable gauge, either because the window between an effective dose and a dangerous one is razor-thin, or because the same pill produces wildly different plasma concentrations from person to person. Therapeutic drug monitoring is the practice of drawing blood at specific intervals and measuring the drug’s plasma concentration directly, then adjusting the dose to keep you in the safe-and-effective range.9PubMed Central. Overview of therapeutic drug monitoring
The drugs that most often require this kind of monitoring fall into predictable categories: those with a narrow therapeutic index (where the gap between a helpful dose and a harmful one is small), those with high patient-to-patient variability in how they are processed, and those where the desired effect is hard to measure by other means. Narrow therapeutic index drugs are the most dramatic example. Because the margin between a safe and lethal dose can be so slim, dosing has to be guided by measured plasma concentrations, and patients need close monitoring for early signs of toxicity.10PubMed Central. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide Classic examples include lithium for bipolar disorder, certain anti-seizure drugs, and immunosuppressants given after organ transplant. Modern mass spectrometry methods have made it feasible to measure multiple drugs simultaneously from a single blood draw, which is particularly useful for patients on complex psychiatric regimens where several medications interact.11PubMed. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring
How Genetics Shift Plasma Concentrations
Your liver breaks down most drugs using a family of enzymes called cytochrome P450. Genetic variations in the genes encoding these enzymes can cause you to process a drug much faster or much slower than average. Research has documented up to a tenfold difference in how quickly people process certain drugs, purely because of inherited differences in a single enzyme.12PubMed. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes In practical terms, that means two people taking the same pill at the same dose can end up with vastly different plasma concentrations, one barely reaching the therapeutic range and the other sitting dangerously high.
These genetic differences depend heavily on ancestry. The enzyme variants that matter most span several cytochrome P450 subtypes, and the frequency of fast-metabolizer versus slow-metabolizer versions varies across ethnic populations.13PubMed. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation This is not just an academic concern. For methadone, a drug where getting the dose right is critical, genetic variants in the CYP2B6 enzyme produce clear, measurable differences in plasma concentrations. People who carry two copies of the *6 variant have roughly double the drug exposure compared to those without it, because they clear the drug more slowly. Carriers of the *4 variant, by contrast, clear the drug much faster and end up with lower plasma levels.14PubMed Central. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism The implication is that a one-size-fits-all methadone dose will reliably undershoot for some patients and overshoot for others, and genetic testing can help predict who falls where.
When Organs Fail, Drug Levels Climb
The kidneys and liver are the body’s main exit routes for drugs. When either organ is compromised, the drug lingers longer in the blood, and plasma concentrations rise. In kidney disease, drug clearance drops and the volume of distribution can increase, both of which alter the concentration profile in unpredictable ways.15PubMed Central. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles But the problem goes beyond simple filtration. Kidney disease generates uremic toxins that interfere with drug transporters in the gut and liver, and it can reduce the liver’s own drug-metabolizing enzyme activity, effectively crippling two clearance pathways at once.16PubMed Central. Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate Standard doses can become unreliable, and the only way to know where a patient actually stands is to measure plasma concentrations directly.
Liver disease creates a parallel problem. Since the liver is where most drugs are chemically transformed before being eliminated, reduced liver function means slower metabolism and higher plasma levels. Liver disease also tends to reduce albumin production, which shifts the bound-to-unbound drug ratio and can amplify the effective dose of highly protein-bound drugs even if the total plasma concentration looks normal.
Your Internal Clock Matters Too
The body’s roughly 24-hour biological clock does not just govern sleep. It influences how you absorb, distribute, metabolize, and excrete drugs, and researchers have documented circadian variation in the plasma concentrations of over a hundred different compounds.17PubMed. The influence of circadian rhythms on the kinetics of drugs in humans Gastric emptying speed, liver blood flow, kidney filtration rate, and enzyme activity all fluctuate throughout the day, and each fluctuation nudges drug absorption or clearance in one direction or another.18PubMed. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy
This has real consequences. A drug taken in the morning may produce a different peak plasma concentration than the same dose taken at night. For most drugs, the variation is modest and clinically irrelevant. But for drugs with narrow therapeutic windows, the time-of-day effect can be large enough to matter, and the field of chronotherapy has emerged to explore whether timing doses to match circadian rhythms can improve effectiveness or reduce side effects.19PubMed Central. Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions Blood pressure medications, chemotherapy agents, and corticosteroids are among the drugs where timing has shown the most promise.
Plasma Concentrations as Diagnostic Tools
Plasma concentration measurement is not limited to drugs. Clinicians routinely measure naturally occurring substances in plasma as markers of disease. C-reactive protein, or CRP, is one of the most widely used. It is produced by the liver in response to inflammation, and elevated plasma CRP levels show up in infections, autoimmune diseases, and cardiovascular conditions.20PubMed Central. Role of C-reactive protein in disease progression, diagnosis and management CRP is not specific to any one disease, but serial measurements after surgery can predict complications like sepsis before clinical symptoms appear.21Archives of Surgery. Diagnostic Implications of C-Reactive Protein Researchers have also found that specific forms of CRP in plasma could help identify acute coronary syndromes in emergency patients who fall into the low-to-moderate risk category.22PubMed. Early verification of myocardial ischemia with a novel biomarker of acute tissue damage: C-reactive protein fractional forms
An even newer frontier involves measuring circulating tumor DNA in plasma. When tumors grow, they shed fragments of their DNA into the bloodstream. By measuring the concentration of this tumor-derived DNA against the background of normal cell-free DNA, clinicians can detect cancer, track its progression, and monitor treatment response without a tissue biopsy. The challenge is that some cancers shed very little. In kidney cancer, for instance, plasma tumor DNA was detectable using standard methods in only about 28% of patients, though more sensitive, personalized approaches pushed detection up to roughly 50%, including in early-stage disease.23PubMed Central. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors Larger tumors and those invading blood vessels were more likely to produce detectable plasma signals.
Why the Blood Draw Itself Can Skew Results
Even a perfectly calibrated lab instrument produces misleading results if the blood sample was mishandled before it arrived. Pre-analytical variables, meaning everything that happens between the needle entering your arm and the sample being analyzed, can introduce errors that look like genuine biological variation. The type of collection tube, the time the blood sits before processing, the temperature it is stored at, the number of times a frozen sample is thawed and refrozen, and the speed and duration of centrifugation all influence what the lab ultimately measures.24PubMed Central. An Overview of Pre-Analytical Factors Impacting Metabolomics Analyses of Blood Samples
In metabolomics research, where the goal is to profile hundreds of small molecules in plasma simultaneously, inconsistent sample processing remains one of the biggest sources of non-biological noise.25PubMed Central. Effects of pre-analytical processes on blood samples used in metabolomics studies For routine clinical labs, the effects are more contained but still real. If your blood sat in a warm transport bag for hours before being spun down, certain metabolites will have risen or fallen in ways that have nothing to do with your health. This is one reason labs have strict protocols for handling specimens, and why results from two different facilities are not always directly comparable.
Plasma Concentrations During Pregnancy
Pregnancy introduces a pharmacokinetic puzzle. A mother’s blood volume expands substantially, diluting drug concentrations. Her kidney filtration rate increases, clearing drugs faster. Hormonal shifts alter liver enzyme activity. And then there is the placenta, which is not just a passive barrier but an active gatekeeper equipped with drug transporters that pump certain medications back toward the mother and away from the fetus.26PubMed. Pharmacology of drug transfer across the placenta The fetal drug concentration is a product of the maternal plasma level, the placenta’s permeability and transporter activity, fetal metabolism, and differences in protein binding between maternal and fetal blood.
Researchers now use physiologically based models to estimate how much drug the fetus is actually exposed to. One way to express this is as a ratio of unbound fetal plasma concentration to unbound maternal plasma concentration at steady state. For drugs that are actively pumped back by placental transporters, this ratio can be surprisingly low. Modeling studies have estimated ratios around 0.35 to 0.41 for drugs like efavirenz, nelfinavir, and imatinib, meaning the fetal unbound concentration sits at roughly 35 to 41% of the maternal level, with placental efflux transporters accounting for the rest of the gap.27PubMed Central. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model These models are becoming increasingly important for guiding drug dosing in pregnancy, where both under-treating the mother and over-exposing the fetus carry real risks.28PubMed Central. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies
Monoclonal Antibodies Play by Different Rules
Most of the pharmacokinetic principles above apply to small-molecule drugs, the kind that come as pills or simple injections. Monoclonal antibodies, the large protein-based therapies used in cancer treatment, autoimmune disease, and beyond, behave differently. Their plasma concentrations often follow nonlinear patterns because the drug binds so tightly to its biological target that the target itself becomes part of the clearance mechanism. When target molecules are abundant, they soak up the antibody and pull it out of circulation faster. As the target gets saturated, clearance slows and plasma concentrations rise disproportionately.29PubMed Central. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies This phenomenon, called target-mediated drug disposition, is frequently observed with monoclonal antibodies and has major implications for how clinical studies are designed and how doses are chosen.30PubMed Central. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
In practice, this means that doubling the dose of a monoclonal antibody does not simply double the plasma concentration. The relationship between dose and concentration curves in unexpected ways, and clinicians have to account for this when interpreting blood levels. It is one reason why biologic therapies are dosed on more complex schedules than traditional drugs, often with loading doses followed by lower maintenance doses calibrated to keep the plasma concentration above the threshold where the target is saturated.